Clinical trial

Impact of Type 2 Diabetes on Outcomes Associated With Antiplatelet Drugs: A Retrospective Analysis

Name
TRHC-T2D-2021-001
Description
Tabula Rasa HealthCare (TRHC), d/b/a CareKinesis, is the first national pharmacy that provides science-based medication risk identification and mitigation technologies and services. CareKinesis utilizes medication decision support tools and pharmacists certified in geriatrics to provide pharmacy services for various healthcare organizations including PACE organizations (described above). Presently, CareKinesis services more than 35 PACE organizations, including approximately 140 PACE sites, across the country. As a national PACE pharmacy provider since 2011, CareKinesis focuses on improving medication regimens to reduce medication-related risks while enhancing economic, clinical and humanistic outcomes. Pharmacist-led clinical services and medication safety reviews are currently being offered to PACE organizations under the direction of licensed healthcare prescribers by TRHC (CareKinesis). Through mutual data-sharing agreements, patient data will be collected retrospectively for patients satisfying the inclusion and exclusion criteria. TRHC via other programs such as the Center for Medicare \& Medicaid Enhanced Medication Therapy Management program with BlueCross BlueShield Northern Plain Alliance and ClearStone, or via collaboration as third party with other health plans can have access to de-identified patient's data. TRHC has also established an agreement with the Watson IBM database to retrieve relevant patients' information for research.
Trial arms
Trial start
2021-09-20
Estimated PCD
2023-01-30
Trial end
2023-01-30
Status
Completed
Treatment
Antiplatelet Drug
Antiplatelet drugs and agents
Arms:
Diabetic patients on antiplatelet drugs other than clopidogrel, Diabetic patients on clopidogrel, Non-diabetic controls on clopidogrel
Other names:
Clopidogrel
Size
173464
Primary endpoint
Measure the prevalence of clopidogrel prescription in patients with T2D in the study population.
1 year
Measure the prevalence of ticagrelor and prasugrel prescription in patients with T2D vs. clopidogrel.
1 year
Calculate MedWise Risk Score (TM) of <10, 11-14, 15-19, 20-30, >30 for T2D patients to examine patient risk for adverse drug events.
1 year
Eligibility criteria
Inclusion Criteria: * Patient is enrolled in a healthcare organization where TRHC provides pharmacy services during the implementation period; or patient's data enrolled with health plan organization having partnership with TRHC; or patient's data from the IBM Watson database. * Patient must be taking anti-platelet medication including clopidogrel, prasugrel, and ticagrelor during the period in which data is collected. Exclusion Criteria: * Patients not taking above mentioned anti-platelet medications during the period in which data is collected
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 173464, 'type': 'ACTUAL'}}
Updated at
2023-01-31

1 organization

1 product

4 indications

Indication
Type 2 Diabetes
Indication
Heart Attack